Clinical trials: Malaria, Uncomplicated
Uncomplicated Malaria
Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria
Plasmodium vivax is the most geographically widespread malaria species and the second largest contributor to symptomatic malaria worldwide.
- Trial name
- NCT07403643
- Testing
- Single dose tafenoquine (10 mg/kg), Dihydroartemisinin-piperaquine (DHA-PPQ), Artemether + Lumefantrine
- Where
- Papua New Guinea
- Volunteers
- 60 people
- Sponsor
- Curtin University
Malaria, Falciparum
Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam
This study is a multi-centre, open-label randomised trial to assess the efficacy, safety and tolerability of the Triple ACT artemether-lumefantrine+amodiaquine (AL+AQ) compared to the ACT artemether-lumefantrine (AL) in…
- Trial name
- TACT-CV (NCT03355664)
- Testing
- ACT, TACT
- Where
- 4 sites in Cambodia, Vietnam
- Volunteers
- 310 people
- Sponsor
- University of Oxford
Malaria
A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria
The purpose of this study is to compare the efficacy of sulfadoxine-pyrimethamine plus artesunate with that of sulfadoxine-pyrimethamine on its own for the treatment of uncomplicated malaria.
- Trial name
- NCT00203736
- Testing
- Sulfadoxine-pyrimethamine, Artesunate plus sulfadoxine-pyrimethamine
- Where
- 2 sites in Mozambique
- Volunteers
- 240 people
- Sponsor
- University of Cape Town
Malaria, Plasmodium Falciparum Malaria
CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi
The purpose of this research study is to find out how well chloroquine works as a drug to treat malaria in children, compared to the standard malaria treatment in Malawi.
- Trial name
- NCT00125489
- Testing
- chloroquine sulfate, sulfadoxine/pyrimethamine
- Where
- Malawi
- Volunteers
- 210 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria,Falciparum, Malaria, Vivax
Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua
Comparing the efficacy of the combination treatment of bitter melon fruit extract (Momordica charantia) with primaquine (MC+PQ) against the combination of dihydroartemisinin + piperaquine + primaquine (DHP+PQ) on patients with…
- Conditions
- Malaria,Falciparum, Malaria, Vivax, Malaria, Infections
- Trial name
- MCMPFPB (NCT06036030)
- Testing
- Dihydroartemisinin, Piperaquine, Primaquine
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Syamsudin Abdillah,Ph.D, Pharm D
Malaria
Dihydroartemisinin-piperaquine and Primaquine for Uncomplicated Plasmodium Falciparum Cases
Artemisinin-based combination therapy (ACT) has been known to be controversial for stopping malaria transmission.The addition of primaquine (PQ) - the only drug commercially available that kills mature transmission stage - to…
- Trial name
- DHP+PQ (NCT01392014)
- Testing
- dihydroartemisinin-piperaquine, dihydroartemisinin-piperaquine + primaquine
- Where
- Indonesia
- Volunteers
- 374 people
- Sponsor
- Universitas Indonesia
Falciparum Malaria
Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda
The purpose of this study is to evaluate the safety and efficacy of lower doses of primaquine compared to the dose recommended by the WHO for reducing P.
- Trial name
- NCT01365598
- Testing
- Primaquine
- Where
- Uganda
- Volunteers
- 468 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection
This study aims to determine the Minimum Inhibitory Concentration of KAE609 in adult male patients with acute, uncomplicated malaria due to P.falciparum monoinfection after single dosing with KAE609
- Trial name
- NCT01836458
- Testing
- KAE609
- Where
- Vietnam
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Efficacy and Safety of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine in Cameroon
Malaria is an infectious disease transmitted by the bite of an infected female anopheles mosquito. The most vulnerable group that bears the highest disease burden includes children less than five years and pregnant women.
- Trial name
- NCT05340153
- Testing
- Artemether-Lumefantrine Drug Combination, Dihydroartemisinin-Piperaquine drug combination
- Volunteers
- 184 people
- Sponsor
- University of Yaounde 1
Uncomplicated Malaria
Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children
We will test the hypothesis that there is a difference in effectiveness of oral quinine in comparison to artemether Lumefantrine in the treatment of uncomplicated malaria in children.
- Trial name
- QALE (NCT00540202)
- Testing
- artemether-lumefantrine, Oral quinine
- Where
- Uganda
- Volunteers
- 302 people
- Sponsor
- Makerere University
Malaria, Falciparum
Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indonesia
This is a prospective, open label, randomised controlled trial to assess the safety and efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum…
- Trial name
- NCT02325180
- Testing
- Dihydroartemisinin-Piperaquine, Artemether-lumefantrine
- Where
- 3 sites in Indonesia
- Volunteers
- 338 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria, Falciparum
Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.
This study will evaluate the safety and efficacy of artemether-lumefantrine against uncomplicated malaria caused P. falciparum in children of 5-35 kg bodyweight.
- Trial name
- NCT00386763
- Testing
- Artemether-lumefantrine
- Where
- 5 sites in Benin, Kenya and 3 more
- Volunteers
- 890 people
- Sponsor
- Novartis
Malaria
Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction in Zanzibar
The purpose of this study is to assess the efficacy of artesuante + amodiaquine four years after its introduction as first line treatment for uncomplicated childhood malaria in Zanzibar.
- Trial name
- NCT00465257
- Testing
- artesunate + amodiaquine
- Where
- Tanzania
- Volunteers
- 110 people
- Sponsor
- Karolinska University Hospital
Malaria, Falciparum
Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa
The primary objective is to confirm the hypothesis that azithromycin used in combination with chloroquine is non-inferior to artemether- Lumefantrine for the treatment of symptomatic, uncomplicated malaria due to P.
- Trial name
- NCT00677833
- Testing
- Azithromycin plus Chloroquine, Artemether-lumefantrine
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 361 people
- Sponsor
- Pfizer
Malaria
A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria
The purpose of this study is to determine the efficacy of sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine alone in the treatment of uncomplicated malaria.
- Trial name
- NCT00203814
- Testing
- Sulfadoxine-pyrimethamine, Artesunate plus sulfadoxine-pyrimethamine
- Where
- 2 sites in Mozambique
- Volunteers
- 280 people
- Sponsor
- University of Cape Town
Falciparum Malaria
Azithromycin Combination Therapy for the Treatment of Severe Malaria
A randomized controlled trial to assess the safety and efficacy of azithromycin combination therapy for use in severe malaria. This pilot trial will be conducted in uncomplicated malaria patients in southeastern Bangladesh.
- Trial name
- NCT01374126
- Testing
- Artesunate, Azithromycin + Artesunate
- Where
- Bangladesh
- Volunteers
- 75 people
- Sponsor
- Medical University of Vienna
Plasmodium Falciparum Malaria (Uncomplicated)
A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.
A partially blinded randomised controlled non-inferiority trial comparing the efficacy, tolerability and safety of Triple ACTs artemether-lumefantrine+amodiaquine (AL+AQ) and artesunate-mefloquine+piperaquine (ASMQ+PPQ) and the…
- Trial name
- DeTACT-Africa (NCT03923725)
- Testing
- Artemether-lumefantrine+ Amodiaquine (AL+AQ), Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)
- Where
- 8 sites in Burkina Faso, Democratic Republic of the Congo and 6 more
- Volunteers
- 2,583 people
- Sponsor
- University of Oxford
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)
This is Cohort B1 of the Platform study (NCT05750628) to evaluate the efficacy and safety of INE963 + Cipargamin in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07811882)
- Testing
- KAE609 (Cipargamin), SoC (Coartem), INE963
- Where
- 13 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Falciparum Malaria
Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Malaria in Cameroon
Malaria remains a major public health concern in Cameroon especially among vulnerable groups such as children less than five years and pregnant women.
- Trial name
- NCT04829695
- Testing
- Artesunate-amodiaquine drug combination, Artemether-lumefantrine drug combination
- Volunteers
- 184 people
- Sponsor
- University of Yaounde 1
Malaria
Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo
This will be an open-randomised non-inferiority study to test the hypothesis that the risk of recurrent parasitaemia after 42 days is not worse in the group receiving the Artesunate-Amodiaquine (ASAQ) regimen than in the group…
- Trial name
- NCT02741024
- Testing
- Amodiaquine-Artesunate (ASAQ), Artemether-Lumefantrine (AL)
- Volunteers
- 288 people
- Sponsor
- Medecins Sans Frontieres, Netherlands